MedTrace Logo

DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)

NCT07786051 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-25

No results posted yet for this study

Summary

This is a single centre, open label, phase II clinical study consisting of two parts, each consisting of a different dose of the same intervention to investigate the efficacy of dexamethasone as an adjunct to endocrine therapy in the treatment of ER+ HER2- metastatic breast cancer after progression on the same endocrine therapy.

Conditions

Interventions

DRUG

Dexamethasone (Oral)

Commercially available Dexamethasone in tablet form 1.5mg or 4mg

Sponsors & Collaborators

  • Oncode Institute

    collaborator UNKNOWN

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Vincent Dezentjé, MD PhD · The Netherlands Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2028-11-01
Completion
2028-11-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07786051 on ClinicalTrials.gov